^
Association details:
| Biomarker: | KRAS G13D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1104 - Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models
Published date:
03/10/2021
Excerpt:
Repotrectinib/trametinib combination in a syngeneic GEMM KRASG12D lung model had greater tumor growth inhibition than either single agent treatment...A similar combination efficacy benefit was observed in a HCT116 (CRC KRASG13D) xenograft model…
